Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

Overview
Date Founded

2016

Headquarters

3027 Townsgate Road,Suite 300,Westlake Village, CA 91361

Type of Company

Public

Employees (Worldwide)

54

Industries

Pharmaceuticals
IT Consulting & Services
Medical Support Services
Biotechnology

Company Description

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Contact Data
Trying to get in touch with decision makers at Arcutis Biotherapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

President & Chief Executive Officer

Chief Financial Officer

Secretary & General Counsel

Chief Digital & Technology Officer

Chief Commercial Officer

Chief Compliance Officer & Chief of Staff

Chief Medical Officer

Chief Business Officer

Chief Technical Officer

Board of Directors

Managing Partner, Life Sciences Team at Frazier Healthcare Partners

Former Venture Partner at ARCH Venture Partners

Chief Legal Officer at NeoGenomics Laboratories, Inc.

Senior Vice President, Chief Information & Transformation Officer at Alcon AG

President, Chief Executive Officer & Director at Phathom Pharmaceuticals, Inc.

Co-Founder at Arcutis Biotherapeutics, Inc.

Swarthmore College

President & Chief Executive Officer at Arcutis Biotherapeutics, Inc.

Former Professor & Chief of Dermatology at Barnes-Jewish Hospital

Paths to Arcutis Biotherapeutics, Inc.
Potential Connections via
Relationship Science
You
Arcutis Biotherapeutics, Inc.
Owners & Shareholders
Details Hidden

Frazier Management invests in companies located in the US with an EBITDA of $5 - $50 million. The firm focuses on companies operating in the fields of Life Science, pharmaceuticals and healthcare services. They provides financing for mezzanine, late private/public opportunities, seed, early and later stage, buyouts, recapitalizations and corporate carve-outs with an investment size of $30 - $350 million.

Details Hidden

Orbimed Advisors Private Equity seeks investment opportunities in private and public healthcare companies located in globally primarily North America, Asia, Europe and Israel. The firm targets companies operating in the fields of biopharmaceutical, medical device, diagnostics and healthcare services. It provides financing for seed stage capital for large publicly traded companies.

Details Hidden

Bain Capital Life Sciences invests in companies located around the world. The firm focuses on sectors such as biopharmaceutical, specialty pharmaceuticals, medical devices, diagnostics, and life science technology. The firm participates in growth capital transactions.

Recent Transactions
Details Hidden

Arcutis Biotherapeutics, Inc. issued USD Common Stock

Details Hidden

Arcutis Biotherapeutics, Inc. issued USD Common Stock

Details Hidden

Arcutis Biotherapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Underwriter

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Underwriter

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Associate

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Counsel

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Scientific Advisor

Director, Eczema & Inflammatory Disease Center at Rady Children's Hospital - San Diego

Scientific Advisor

Chairman, Department of Dermatology at Icahn School of Medicine at Mount Sinai

Scientific Advisor

Vice President at Astellas Pharma, Inc.

Key Stats and Financials As of 2020
Market Capitalization
$892M
Total Enterprise Value
$722M
Earnings Per Share
$-3.8
Three Year Compounded Annual Growth Rate Of Revenue
0%
Debt TEV
0.01x
TEVNet Income
-5.32x
Total Equity
$271M
Total Debt
$4.96M
EBITDA
$-136M
Net Profit
$-136M
Revenue
$0
Investors
Details Hidden

Frazier Management invests in companies located in the US with an EBITDA of $5 - $50 million. The firm focuses on companies operating in the fields of Life Science, pharmaceuticals and healthcare services. They provides financing for mezzanine, late private/public opportunities, seed, early and later stage, buyouts, recapitalizations and corporate carve-outs with an investment size of $30 - $350 million.

Details Hidden

Orbimed Advisors Private Equity seeks investment opportunities in private and public healthcare companies located in globally primarily North America, Asia, Europe and Israel. The firm targets companies operating in the fields of biopharmaceutical, medical device, diagnostics and healthcare services. It provides financing for seed stage capital for large publicly traded companies.

Details Hidden

Pivotal Bioventure invests in companies located in the US and Europe. The firm targets companies operating in the fields of biotechnology and innovative therapeutic products. It provides financing for seed, early and later-stage capital requirements.

Suppliers
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Industrial Machinery & Manufacturing | Lianyungang, China

Jiangsu Hengrui Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The firm’s products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

AstraZeneca Plc Other Manufacturing | Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, Canada

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Arcutis Biotherapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Arcutis Biotherapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Arcutis Biotherapeutics, Inc..